Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Total Current Liabilities (2018 - 2025)

Black Diamond Therapeutics' Total Current Liabilities history spans 6 years, with the latest figure at $15.7 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 23.54% year-over-year to $15.7 million; the TTM value through Dec 2025 reached $15.7 million, down 23.54%, while the annual FY2025 figure was $15.7 million, 23.54% down from the prior year.
  • Total Current Liabilities reached $15.7 million in Q4 2025 per BDTX's latest filing, up from $15.5 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $26.4 million in Q3 2021 to a low of $15.5 million in Q3 2025.
  • Average Total Current Liabilities over 3 years is $19.1 million, with a median of $18.4 million recorded in 2024.
  • Peak YoY movement for Total Current Liabilities: soared 282.57% in 2021, then decreased 25.26% in 2025.
  • A 3-year view of Total Current Liabilities shows it stood at $26.4 million in 2021, then fell by 21.96% to $20.6 million in 2024, then decreased by 23.54% to $15.7 million in 2025.
  • Per Business Quant, the three most recent readings for BDTX's Total Current Liabilities are $15.7 million (Q4 2025), $15.5 million (Q3 2025), and $16.8 million (Q2 2025).